ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO755

Kidney Tubule Injury and Dysfunction Biomarkers and Risk of Incident Hypertension in Community-Living Individuals: Results From the Multi-Ethnic Study of Atherosclerosis

Session Information

Category: Hypertension and CVD

  • 1502 Hypertension and CVD: Clinical‚ Outcomes‚ and Trials


  • Malhotra, Rakesh, University of California San Diego, La Jolla, California, United States
  • Katz, Ronit, University of Washington, Seattle, Washington, United States
  • Kimmel, Paul L., National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States
  • Ramachandran, Vasan S., Boston University School of Medicine, Boston, Massachusetts, United States
  • Al-Rousan, Tala, University of California San Diego, La Jolla, California, United States
  • Greenberg, Jason Henry, Yale University, New Haven, Connecticut, United States
  • Parikh, Chirag R., Johns Hopkins University, Baltimore, Maryland, United States
  • Bonventre, Joseph V., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Schelling, Jeffrey R., University Hospitals, Cleveland, Ohio, United States
  • Sarnak, Mark J., Tufts Medical Center, Boston, Massachusetts, United States
  • Gutierrez, Orlando M., UAB Health System, Birmingham, Alabama, United States
  • Shlipak, Michael, UCSF Medical Center, San Francisco, California, United States
  • Ix, Joachim H., University of California San Diego, La Jolla, California, United States

Hypertension (HTN) is a major risk factor for the onset and progression of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, the mechanisms leading to essential HTN remain elusive. Here, we evaluated the association between tubule biomarkers and risk of developing HTN.


We randomly sampled 463 MESA participants who did not have prevalent CKD or diabetes, but excluded 166 participants who had prevalent HTN. We measured six plasma tubule biomarkers (KIM-1, MCP-1, suPAR, TNFR1, TNFR2 and YKL-40) and five urinary tubule biomarkers (EGF, KIM-1, MCP-1, YKL-40 and urine albumin) at baseline. The primary outcome was the development of incident HTN, defined as either a systolic BP≥ 140 mmHg, a diastolic BP ≥ 90 mmHg, or the use of any antihypertensive medication during a follow-up period. Multivariable Poisson regression was used to examine associations between baseline kidney tubule markers and urine albumin with incident HTN.


Among the 297 participants, the mean age was 58±10 years, 53% were women, 47% were White, and 20% were Black. The median number of BP measurements per participant was 6 (IQR 2 to 10). Nearly half (N=142) developed incident HTN event over 15 years of follow-up. In unadjusted models, higher urinary KIM-1, MCP-1 and urine albumin, as well as higher plasma MCP-1 and YKL-40 were individually associated with risk of incident HTN (Figure 1). However, in the fully adjusted model, only urine albumin remained associated with incident HTN (IRR 1.25 (1.1 to 1.5); P < .005).


In this study of community-living individuals without CKD, diabetes, or CVD, in an adjusted model there was no association of selected kidney tubule injury or dysfunction biomarkers with incident HTN. In comparison, urine albumin was independently associated with incident HTN.


  • NIDDK Support